27 min listen
Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms
FromThe Hematologist
Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms
FromThe Hematologist
ratings:
Length:
24 minutes
Released:
Jun 21, 2024
Format:
Podcast episode
Description
In this episode, Contributing Editor Bethan Psaila, MD, PhD, an associate professor of hematology at the University of Oxford’s MRC Weatherall Institute of Molecular Medicine, talks with Andrew Dunbar, MD, an assistant professor and independent lab investigator at MD Anderson Cancer Center in Houston, Texas. They discuss Dr. Dunbar’s paper recently published in Cancer Discovery: “JAK2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms.”
Released:
Jun 21, 2024
Format:
Podcast episode
Titles in the series (100)
BCL-2 Is an Effective Target in Chronic Lymphocytic Leukemia: In her Diffusion article from the May/June issue of The Hematologist, Dr. Ann LaCasce (Dana-Farber Cancer Institute) discusses the use of the recently FDA-approved drug venetoclax for the treatment of patients with chronic lymphocytic leukemia (CLL) or sm by The Hematologist